American Aquarium Products sells unapproved, misbranded antimicrobial drugs for aquarium fish, FDA says.
What happened
In August 2023, FDA reviewed the company’s website, where it takes orders for AAP Aquatronics Discomed, Myacin, and Spectrogram. FDA found claims that the products treat or prevent disease in aquarium fish, making them drugs. FDA says the products are unapproved new animal drugs and are misbranded because they are not drug listed and were not made in an FDA-registered facility.
What FDA found
FDA says the products are unapproved new animal drugs because they have no approved application, conditional approval, or index listing.
FD&C Act §§ 512, 571, 572 [21 U.S.C. §§ 360b, 360ccc, 360ccc-1]FDA says the products are misbranded because they have not been drug listed with FDA.
FD&C Act § 502(o) [21 U.S.C. § 352(o)]FDA says the products are misbranded because they were not made in an FDA-registered facility.
FD&C Act §§ 510(b), 510(j), 502(o) [21 U.S.C. §§ 360(b), 360(j), 352(o)]FDA says website claims show the products are intended to cure, mitigate, treat, or prevent disease in fish, which makes them drugs.
FD&C Act § 201(g)(1)(B) [21 U.S.C. § 321(g)(1)(B)]FDA says the products are unsafe and adulterated because they lack the required approval or index listing.
FD&C Act §§ 512(a), 501(a)(5) [21 U.S.C. §§ 360b(a), 351(a)(5)]FDA says introducing or delivering these unapproved and misbranded drugs into interstate commerce is prohibited.
FD&C Act § 301(a) [21 U.S.C. § 331(a)]
What FDA wants
Within 15 working days, FDA asks the company to write to the agency with the specific steps taken to correct violations, steps to prevent recurrence, and related documentation. If corrections cannot be completed in that time, the company must state why and when it will finish.
Who should pay attention
- aquarium fish drug sellers
- veterinary drug repackers and relabelers
- companies marketing antimicrobials for minor species
This is a summary. Read the original letter on fda.gov.